depression

News

Text message therapy for depression works in young adults

Young adults with depression have been treated effectively with a cognitive behavioural therapy (CBT) course – delivered via text message – in a pilot study conducted by researchers in the

News

Axsome bounces back as FDA clears depression drug

Shares in Axsome Therapeutics have rocketed on FDA approval of its depression therapy Auvelity (formerly AXS-05) – a year after its approval was

Digital

Building a digital therapeutic for paediatric behavioural he...

On the latest instalment of the pharmaphorum podcast, editor in chief Jonah Comstock hosts Dr Benny Alouf, chief medical officer at Limbix to discuss his company’s digital therapeutic for teen depr

News

Praxis wields the axe as lead depression drug fails

Shares in Praxis Precision Medicines were in freefall today after the company's efforts to develop a new therapy for major depressive disorder (MDD) ended in failure, forcing a restructurin

News

AbbVie adds to Vraylar data as FDA considers depression use

AbbVie has reported new phase 3 data for its schizophrenia and bipolar disorder therapy Vraylar in treatment-resistant depression, as it waits for a decision by the FDA on the new indicatio

News

Beckley adds digital element to its psychedelic drug trials

Phase 2 trials of Beckley Psytech's psychedelic drug candidates will make use of digital technologies for patient monitoring, thanks to a new partnership with Empatica.

Text message therapy for depression works in young adults

Axsome bounces back as FDA clears depression drug

Building a digital therapeutic for paediatric behavioural he...

Praxis wields the axe as lead depression drug fails

AbbVie adds to Vraylar data as FDA considers depression use

Beckley adds digital element to its psychedelic drug trials

Praxis soars on rare childhood epilepsy trial data

How to meet your physicians where they are online

depression

Editor's Picks